RecruitingNCT04433455Updated Sep 23, 2026

Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients

An observational study in Hemodialysis, Cognitive Impairment and Cerebrovascular Disorders, sponsored by Huashan Hospital. Recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Huashan Hospital · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 20
Ages: 50 Years to 85 Years
Sex: All

Study summary

In this observational study, the investigators evaluate the influencing factors of cerebrovascular disease and cognition in hemodialysis patients.

Conditions studied

Hemodialysis
Cognitive Impairment
Cerebrovascular Disorders

Browse trials for

Who can participate

Ages eligible: 50 Years to 85 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

maintenance hemodialysis patients

Inclusion criteria

maintenance hemodialysis patients who are younger than 85 years old and older than 50 years old, regardless of gender
dialysis vintage is greater than 3 months;

Exclusion criteria

Exclusion Criteria:

Those with severe infection and anemia (Hb \<60g / L);
Those with severe mental illness, metabolic diseases and immune system diseases;
Patients with abnormal liver function

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 20 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

cerebrovascular disease
Magnetic resonance images will be used to determine the severity of white matter hyperintensity, using the Scheltens scale. Score 2 or more is abnormal.
Time frame: 5 years

Secondary outcomes

changes in cognitive function
The Mini-Mental State Examination (MMSE) will be used to assess the changes in cognitive function.The MMSE has a maximum score of 30 points. The scores are generally grouped as follows: 25-30 points: normal cognition 21-24 points: mild dementia 10-20 points: moderate dementia 9 points or lower: severe dementiaThe Mini-Mental State Examination (MMSE) will be used to assess the changes in cognitive function.The MMSE has a maximum score of 30 points. The scores are generally grouped as follows: 25-30 points: normal cognition 21-24 points: mild dementia 10-20 points: moderate dementia 9 points or lower: severe dementia
Time frame: 5 years

Study locations

1 of 1 sites recruiting

Huashan Hospital
Shanghai, Shanghai Municipality 200040, China
- Qian Zhang · Contact
Recruiting

Registry details

Key details

Study ID: NCT04433455
Lead sponsor: Huashan Hospital
Responsible party: Chen Jing (Professor, Huashan Hospital) — Principal investigator
First posted: Jun 16, 2020
Start date: Jun 1, 2020
Primary completion: Dec 31, 2026 (estimated)
Completion: Dec 31, 2026 (estimated)
Last update: Sep 23, 2026

Study contacts

Jing Chen

Contact

chenjing1998@fudan.edu.cn

862152889325

Jing Chen

principal investigator · Huashan Hospital

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cognitive Dysfunction→

Other studies from this sponsor

Huashan Hospital

Start the discussion